This efficacy was enhanced by pharmacological agents, such as histone deacetylase inhibitors (HDACi), which upregulate the expression of NKG2D ligands and render AML cells more susceptible to immune attack [44,67]. Here, KLRK1 is linked to acute myeloid leukemia.